Shilpa Medicare Limited (SHILPAMED.BO)
- Previous Close
530.35 - Open
526.05 - Bid 540.35 x --
- Ask 545.50 x --
- Day's Range
526.00 - 548.90 - 52 Week Range
228.25 - 558.00 - Volume
27,032 - Avg. Volume
55,200 - Market Cap (intraday)
53.345B - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
-- - EPS (TTM)
-0.05 - Earnings Date May 23, 2024 - May 27, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 19, 2022
- 1y Target Est
528.50
Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (APIs), finished dosage formulations, biologicals, and other allopathic pharmaceutical preparations in India, the United States, Europe, and internationally. It's primary oncology APIs include capecitabine, gemcitabine hydrochloride, pemetrexed, axitinib, erlotinib hydrochloride, and irinotecan hydrochloride; and non-oncology APIs, such as ambroxol, tranexmic acid, and ursodeoxycholic acid; as well as novel-drug delivery systems. The company provides contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, and lyophilized injectables. In addition, it is involved in manufacture of specialized oncology formulations; and wind power generation activities. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.
www.vbshilpa.com1,179
Full Time Employees
March 31
Fiscal Year Ends
Sector
Related News
Performance Overview: SHILPAMED.BO
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SHILPAMED.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SHILPAMED.BO
Valuation Measures
Market Cap
53.34B
Enterprise Value
61.69B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.23
Price/Book (mrq)
2.99
Enterprise Value/Revenue
5.52
Enterprise Value/EBITDA
29.06
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.06%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
11.25B
Net Income Avi to Common (ttm)
-6.71M
Diluted EPS (ttm)
-0.05
Balance Sheet and Cash Flow
Total Cash (mrq)
239.78M
Total Debt/Equity (mrq)
48.77%
Levered Free Cash Flow (ttm)
--
Research Analysis: SHILPAMED.BO
Company Insights: SHILPAMED.BO
SHILPAMED.BO does not have Company Insights